SynthesisCNS neuroscience & therapeutics2025
Albiflorin on Neuropsychiatric and Neurodegenerative Disorders: A Systematic Review.
Synthesis in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Albiflorin on Neuropsychiatric and Neurodegenerative Disorders: A Systematic Review.CNS neuroscience & therapeutics · 2025Pooled it
- Integrated experimental and network pharmacology analyses reveal inhibitory effects of albiflorin on renal cell carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsAlbiflorin, a key compound from Paeonia lactiflora, has shown therapeutic potential in neuropsychiatric and neurodegenerative disorders (NPDs and NDDs), especially depression and Alzheimer's disease (AD). This review aimed to summarize its pharmacological effects, mechanisms, pharmacokinetics, and therapeutic prospects. DISCUSSION: Albiflorin exhibits multi-target actions, including modulation of monoamine neurotransmitters, inhibition of neuroinflammation, and enhancement of neuroplasticity. In AD, it reduces Aβ accumulation, improves mitochondrial function, and activates MAPK/ERK and Nrf2/HO-1 signaling pathways. In depression, it restores phospholipid and tryptophan metabolism, regulates HPA axis function, and increases BDNF expression. Albiflorin crosses the blood-brain barrier (BBB) and may act indirectly via the gut-brain axis through its metabolite benzoic acid. Though brain concentrations are low, its pharmacological effects remain significant. Albiflorin also shows potential benefits in conditions like cerebral ischemia and hypoxic-ischemic brain injury. Toxicological data indicate low systemic toxicity and good safety margins in vivo and in vitro.
conclusionsAlbiflorin demonstrates promising therapeutic potential for NPDs and NDDs via multi-pathway regulation. However, further studies are needed to optimize brain delivery, understand gut microbiota interactions, and confirm efficacy through clinical trials. The advancement of formulation strategies and pharmacokinetic research will be considered key to achieving clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.